A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Stopped Sponsor Decision: The trial has been withdrawn with no plans to continue development.

Conditions

• Relapsing Multiple Sclerosis
• Multiple Sclerosis

Interventions

• DRUG: Placebo
• DRUG: Pirtobrutinib

Sponsor

Loxo Oncology, Inc.

Collaborators

• [object Object]